Daxor (DXR) vs TELA Bio (TELA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Daxor (DXR) has outperformed TELA Bio (TELA) over the past year, losing 18.2% versus a loss of 25.0%. Over five years, DXR leads with a -7.5% price change compared with -91.2% for TELA. Daxor is the larger company by market cap ($60.8 million vs $50.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | TELA |
|---|---|---|
| Share price | $10.41 | $1.11 |
| Market cap | $60.78M | $50.11M |
| 1-day change | -0.48% | +5.71% |
| YTD return | -29.42% | -5.93% |
| 1-year return | -18.22% | -25.00% |
| 5-year return | -7.47% | -91.19% |
| P/E ratio (TTM) | 9.46 | — |
| EPS (TTM) | $1.10 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $1.56 |
| 52-week low | $8.56 | $0.501 |
| Distance from 52-week high | -29.47% | -28.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.12% | +87.39% |
| Average volume | 17.27K | 214.83K |
| Shares outstanding | 5.84M | 45.14M |
| Employees | — | 218 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About TELA Bio
TELA stock →TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Health Care · Medical/Dental Instruments · 218 employees
DXR vs TELA FAQ
Which is bigger, Daxor or TELA Bio?
Daxor (DXR) is larger, with a market capitalization of $60.78M compared with $50.11M for TELA Bio (TELA).
Which stock has performed better over the past year, DXR or TELA?
DXR returned -18.22% over the past 12 months, compared with -25.00% for TELA (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and TELA Bio in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.